Capio La Croix Du Sud
- Address
- lock Available on a paid plan
Capio La Croix Du Sud - Oncology and Urology Research Center
Capio La Croix Du Sud is a distinguished clinical research center specializing in advanced oncology and urological conditions. The center demonstrates particular expertise in prostate cancer management, conducting multiple innovative trials evaluating novel hormonal therapies in perioperative settings, as well as pioneering research in breast cancer immunotherapy and germ cell tumor management.
- Advanced prostate cancer research with perioperative androgen deprivation therapy and next-generation androgen receptor inhibitors
- Triple negative breast cancer trials combining chemoimmunotherapy with novel post-operative treatment strategies
- Urological interventions including kidney stone management and thromboprophylaxis in advanced germ cell tumors
The center's research portfolio reflects a comprehensive approach to genitourinary oncology, with particular emphasis on high-risk and locally advanced cancers. Their work spans from surgical interventions and perioperative care to advanced systemic therapies, including immunotherapy combinations and targeted hormonal treatments. The facility's involvement in multicenter trials evaluating both oncologic outcomes and supportive care measures, such as venous thromboembolism prevention in cancer patients, demonstrates their commitment to holistic patient care and evidence-based medicine.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 6 therapeutic areas and 15 of 79 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 75 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
- 1Janssen Cilag International2active
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International6trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Capio La Croix Du Sud
lock Showing 1 of 29 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator’s Choice of Intravesical Chemotherapy in Participants with High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG) | Janssen Cilag International | Phase III | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 79 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Gemcitabine Hydrochloride | 5 | Unknown | 2022-01-09 | 2025-12-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.